Standard Biotools Inc (LAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Standard Biotools Inc (LAB) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.20 Million) by net assets ($399.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Standard Biotools Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Standard Biotools Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Standard Biotools Inc for a breakdown of total debt and financial obligations.
Standard Biotools Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Standard Biotools Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polisan Holding AS
IS:POLHO
|
0.019x |
|
Steel Strips Wheels Limited
NSE:SSWL
|
0.058x |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
-0.060x |
|
Jupiter Mines Ltd
AU:JMS
|
0.001x |
|
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
|
0.058x |
|
John Wiley & Sons B
NYSE:WLYB
|
0.011x |
|
Viking Line Abp
HE:VIK1V
|
0.151x |
|
Liuzhou Chemical Industry Co Ltd
SHG:600423
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Standard Biotools Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of Standard Biotools Inc from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see LAB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $471.72 Million | $-143.45 Million | -0.304x | -204.01% |
| 2023-12-31 | $-148.05 Million | $-43.29 Million | 0.292x | -73.35% |
| 2022-12-31 | $-81.47 Million | $-89.37 Million | 1.097x | +335.52% |
| 2021-12-31 | $94.60 Million | $-44.06 Million | -0.466x | -320.10% |
| 2020-12-31 | $139.05 Million | $-15.42 Million | -0.111x | +51.63% |
| 2019-12-31 | $153.61 Million | $-35.21 Million | -0.229x | +34.41% |
| 2018-12-31 | $72.12 Million | $-25.20 Million | -0.349x | +55.14% |
| 2017-12-31 | $30.93 Million | $-24.10 Million | -0.779x | -6.06% |
| 2016-12-31 | $53.23 Million | $-39.10 Million | -0.734x | -143.23% |
| 2015-12-31 | $114.90 Million | $-34.70 Million | -0.302x | -100.77% |
| 2014-12-31 | $150.42 Million | $-22.62 Million | -0.150x | -818.07% |
| 2013-12-31 | $97.12 Million | $-1.59 Million | -0.016x | +90.57% |
| 2012-12-31 | $100.66 Million | $-17.48 Million | -0.174x | +43.68% |
| 2011-12-31 | $56.90 Million | $-17.54 Million | -0.308x | -606.80% |
| 2010-12-31 | $-189.17 Million | $-11.51 Million | 0.061x | -45.87% |
| 2009-12-31 | $-173.62 Million | $-19.51 Million | 0.112x | -38.04% |
| 2008-12-31 | $-158.34 Million | $-28.72 Million | 0.181x | +8.64% |
| 2007-12-31 | $-130.33 Million | $-21.76 Million | 0.167x | -20.53% |
| 2006-12-31 | $-106.17 Million | $-22.31 Million | 0.210x | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consum… Read more